- Home
- MVF vs MREO Comparison
MVF vs MREO Comparison
Compare MVF & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MVF
- MREO
- Stock Information
- Founded
- MVF 1988
- MREO 2015
- Country
- MVF United States
- MREO United Kingdom
- Employees
- MVF N/A
- MREO N/A
- Industry
- MVF Investment Bankers/Brokers/Service
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- MVF Finance
- MREO Health Care
- Exchange
- MVF Nasdaq
- MREO Nasdaq
- Market Cap
- MVF 375.5M
- MREO 438.8M
- IPO Year
- MVF N/A
- MREO N/A
- Fundamental
- Price
- MVF $6.66
- MREO $1.63
- Analyst Decision
- MVF
- MREO Strong Buy
- Analyst Count
- MVF 0
- MREO 5
- Target Price
- MVF N/A
- MREO $7.20
- AVG Volume (30 Days)
- MVF 162.8K
- MREO 4.4M
- Earning Date
- MVF 01-01-0001
- MREO 08-12-2025
- Dividend Yield
- MVF 4.11%
- MREO N/A
- EPS Growth
- MVF N/A
- MREO N/A
- EPS
- MVF N/A
- MREO N/A
- Revenue
- MVF N/A
- MREO N/A
- Revenue This Year
- MVF N/A
- MREO N/A
- Revenue Next Year
- MVF N/A
- MREO $38.38
- P/E Ratio
- MVF N/A
- MREO N/A
- Revenue Growth
- MVF N/A
- MREO N/A
- 52 Week Low
- MVF $5.85
- MREO $1.57
- 52 Week High
- MVF $7.19
- MREO $5.02
- Technical
- Relative Strength Index (RSI)
- MVF 59.92
- MREO 32.17
- Support Level
- MVF $6.43
- MREO $1.71
- Resistance Level
- MVF $6.67
- MREO $1.83
- Average True Range (ATR)
- MVF 0.05
- MREO 0.09
- MACD
- MVF 0.02
- MREO 0.01
- Stochastic Oscillator
- MVF 95.83
- MREO 0.00
About MVF Blackrock MuniVest Fund Inc.
Blackrock Munivest Fund Inc is an investment management firm. Its investment objective is to provide current income exempt from regular U.S. federal income tax. The company invests in various sectors such as Health; Transportation; Utilities; Education; Tobacco; Housing and others.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).